RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-7.93%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$973M
AUM Growth
+$973M
(-21%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-14.06%
Top 10 Holdings %
Top 10 Hldgs %
31.9%
Holding
97
New
2
Increased
29
Reduced
54
Closed
5
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$13.1M |
| 2 |
Cigna
CI
|
$10.1M |
| 3 |
Biogen
BIIB
|
$8.66M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$6.47M |
| 5 |
Humana
HUM
|
$6.15M |
Top Sells
| 1 |
Natera
NTRA
|
$17M |
| 2 |
Becton Dickinson
BDX
|
$14.7M |
| 3 |
Boston Scientific
BSX
|
$13M |
| 4 |
HCA Healthcare
HCA
|
$12.6M |
| 5 |
Glaukos
GKOS
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
IQVIA
IQV
$31.4B
| $5.7M | 0.59% |
29,000
-19,000
| -40% | -$3.73M |
|
52
Nuvalent
NUVL
$5.74B
| $5.68M | 0.58% |
72,500
-17,500
| -19% | -$1.37M |
|
53
Universal Health Services
UHS
$11.6B
| $5.54M | 0.57% |
30,900
+22,900
| +286% | +$4.11M |
|
|
54
Glaukos
GKOS
$5.42B
| $5.48M | 0.56% |
36,531
-74,469
| -67% | -$11.2M |
|
55
Nurix Therapeutics
NRIX
$723M
| $5.46M | 0.56% |
290,000
-10,000
| -3% | -$188K |
|
56
Encompass Health
EHC
$12.5B
| $5.17M | 0.53% |
56,000
-5,000
| -8% | -$462K |
|
57
Xencor
XNCR
$594M
| $4.5M | 0.46% |
195,750
-8,000
| -4% | -$184K |
|
58
Novo Nordisk
NVO
$252B
| $4.3M | 0.44% |
50,000
-50,000
| -50% | -$4.3M |
|
59
Insmed
INSM
$30.3B
| $4.25M | 0.44% |
61,500
-68,013
| -53% | -$4.7M |
|
60
Esperion Therapeutics
ESPR
$490M
| $4.21M | 0.43% |
1,915,000
-60,000
| -3% | -$132K |
|
61
Alnylam Pharmaceuticals
ALNY
$58.6B
| $4M | 0.41% |
17,000
-33,350
| -66% | -$7.85M |
|
62
Krystal Biotech
KRYS
$4.35B
| $3.72M | 0.38% |
23,750
+6,750
| +40% | +$1.06M |
|
63
Viking Therapeutics
VKTX
$3.02B
| $3.62M | 0.37% |
90,000
-12,500
| -12% | -$503K |
|
64
Immunovant
IMVT
$2.91B
| $3.59M | 0.37% |
145,000
-98,000
| -40% | -$2.43M |
|
65
Geron
GERN
$893M
| $3.54M | 0.36% |
1,000,000
| – | – |
|
66
Arcellx
ACLX
$3.95B
| $3.34M | 0.34% |
43,500
+11,500
| +36% | +$882K |
|
67
Merus
MRUS
$5.04B
| $3.13M | 0.32% |
74,500
-5,000
| -6% | -$210K |
|
68
Syndax Pharmaceuticals
SNDX
$1.39B
| $3.07M | 0.32% |
232,000
-27,500
| -11% | -$364K |
|
69
Mirum Pharmaceuticals
MIRM
$3.75B
| $3.05M | 0.31% |
73,755
-31,245
| -30% | -$1.29M |
|
70
Arvinas
ARVN
$580M
| $2.98M | 0.31% |
155,500
+25,000
| +19% | +$479K |
|
71
Annexon
ANNX
$225M
| $2.78M | 0.29% |
542,500
-17,500
| -3% | -$89.8K |
|
72
Charles River Laboratories
CRL
$7.99B
| $2.74M | 0.28% |
14,850
-22,650
| -60% | -$4.18M |
|
73
Kura Oncology
KURA
$732M
| $2.74M | 0.28% |
314,526
+148,000
| +89% | +$1.29M |
|
74
Astrana Health
ASTH
$1.42B
| $2.52M | 0.26% |
+80,000
| New | +$2.52M |
|
75
Dianthus Therapeutics
DNTH
$781M
| $2.49M | 0.26% |
114,000
-36,000
| -24% | -$785K |
|